These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 26152237)
1. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E; BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237 [TBL] [Abstract][Full Text] [Related]
2. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344 [TBL] [Abstract][Full Text] [Related]
4. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. Alvarez-Uria G; Ratcliffe L; Vilar J HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695 [TBL] [Abstract][Full Text] [Related]
6. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592 [TBL] [Abstract][Full Text] [Related]
7. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients. Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598 [TBL] [Abstract][Full Text] [Related]
8. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883 [TBL] [Abstract][Full Text] [Related]
10. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093 [TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224 [TBL] [Abstract][Full Text] [Related]
13. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis. Naing C; Poovorawan Y; Tong KS BMC Infect Dis; 2018 Nov; 18(1):564. PubMed ID: 30428847 [TBL] [Abstract][Full Text] [Related]
15. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302 [TBL] [Abstract][Full Text] [Related]
16. High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China. Jia HH; Li KW; Chen QY; Wang XY; Harrison TJ; Liang SJ; Yang QL; Wang C; Hu LP; Ren CC; Fang ZL Intervirology; 2018; 61(3):123-132. PubMed ID: 30368502 [TBL] [Abstract][Full Text] [Related]
17. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996 [TBL] [Abstract][Full Text] [Related]